BY EU STUDIO

Updated Monday, October 17, 2022-09:39

  • Share on Facebook

  • Share on Twitter

  • send by email

New cases of cancer will experience a slight increase in Spain this year.

A total of 280,100 new cases are estimated, according to data from the Spanish Network of Cancer Registries.

Today, breast cancer is the most common type of tumor and about one in 12 women will develop this disease in their lifetime.

Even so, the prognosis of cancer patients has improved a lot in recent years thanks, above all, to research and the development of new targeted therapies.

In the specific case of breast cancer, it has increased patient survival rates.

For this reason, breast cancer is "one of the tumors with the best expectations, with 87% survival," says Naiara Cambas, director of scientific dissemination at the Scientific Foundation of the Spanish Association Against Cancer.

But she, she reminds her, still needs to emphasize the power of research around this disease.

The current challenge of new cancer treatments is, in part, to treat tumors with metastases in other organs, mainly in the brain, where most therapies cannot reach tumor cells.

Here, HER2-positive tumors stand out, which affect about 20% of breast cancers.

Although these highly aggressive tumors are treated with specific drugs, their effect is limited.

In fact, more than 7,000 patients a year in Spain do not respond well to these therapies.

For all these reasons, to continue fighting this disease it is essential to invest even more in research.

In this sense, and within the framework of the World Day Against Breast Cancer that is celebrated every October 19, the company Sabadell Seguros promotes the advances of a study that will allow the design of new personalized therapies in cancer patients with this type of tumor, highly prone to metastasize.

The future of cancer treatments

Through the Life Care Mujer life insurance, the entity will donate 10,000 euros to the "Development of new therapies for HER2+ breast cancer" project, led by Dr. Gema Moreno and backed by the Spanish Association Against Cancer (AECC).

Its results will allow, on the one hand, to develop personalized therapies;

and, on the other, that they are less toxic and more specific.

In addition, this study aims to help prevent tumor resistance to anti-HER2 therapies and, in turn, prevent metastasis, especially to the brain.

Its ultimate goal is "to develop new and patentable therapeutic options that can be transferred in the near future to patients with these aggressive tumors," points out Dr. Gema Moreno.

For her, "cancer is a pandemic that affects us all directly or indirectly."

The project financed by the Spanish Association Against Cancer is, for the doctor, "vital for society" and focuses on the identification of treatments directed against a molecule called Gasdermin B (GSDMB) whose high levels in tumors are associated with resistance to conventional therapy.

At Sabadell Seguros they are very aware of the determining role of medical research.

Bernardino Gómez, general director of the company, points out that it is important that entities and society bet on research to "make a better world".

The firm, in this sense, goes a step further.

Thus, for each Life Care Woman life insurance policy registered, Sabadell Seguros donates three euros to research against female cancer.

In this way, Gómez Aritmendi concludes, "we manage to return something to society that has trusted us".

The objective, after all, is to minimize the economic and psychological impact that the oncological process entails.

And make life more bearable for all patients.

Made by UE Studio

This text has been developed by UE Studio, a creative branded content and content marketing firm from Unidad Editorial, for BANCO SABADELL.

Conforms to The Trust Project criteria

Know more